Correlation Between Nuvectis Pharma and Biomea Fusion

Can any of the company-specific risk be diversified away by investing in both Nuvectis Pharma and Biomea Fusion at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nuvectis Pharma and Biomea Fusion into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Nuvectis Pharma and Biomea Fusion, you can compare the effects of market volatilities on Nuvectis Pharma and Biomea Fusion and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nuvectis Pharma with a short position of Biomea Fusion. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nuvectis Pharma and Biomea Fusion.

Diversification Opportunities for Nuvectis Pharma and Biomea Fusion

0.33

Correlation Coefficient

Nuvectis Pharma  Biomea Fusion

Weak diversification

The 3 months correlation between Nuvectis and Biomea is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Nuvectis Pharma and Biomea Fusion in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biomea Fusion and Nuvectis Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nuvectis Pharma are associated (or correlated) with Biomea Fusion. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biomea Fusion has no effect on the direction of Nuvectis Pharma i.e., Nuvectis Pharma and Biomea Fusion go up and down completely randomly.

Pair Corralation between Nuvectis Pharma and Biomea Fusion

Given the investment horizon of 90 days Nuvectis Pharma is expected to generate 3.26 times more return on investment than Biomea Fusion. However, Nuvectis Pharma is 3.26 times more volatile than Biomea Fusion. It trades about 0.0 of its potential returns per unit of risk. Biomea Fusion is currently generating about -0.26 per unit of risk. If you would invest  631.00  in Nuvectis Pharma on September 5, 2024 and sell it today you would lose (134.00) from holding Nuvectis Pharma or give up 21.24% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Nuvectis Pharma  vs.  Biomea Fusion

Nuvectis Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Nuvectis Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Nuvectis Pharma is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Biomea Fusion

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Biomea Fusion has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong technical and fundamental indicators, Biomea Fusion is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Nuvectis Pharma and Biomea Fusion

The main advantage of trading using opposite Nuvectis Pharma and Biomea Fusion positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nuvectis Pharma position performs unexpectedly, Biomea Fusion can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomea Fusion will offset losses from the drop in Biomea Fusion's long position.

The idea behind Nuvectis Pharma and Biomea Fusion pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.